LIVIVO - Search results -

Search results

Result 1 - 10 of total 223

Search options

Article ; Online: Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.

Mi, Jian-Qing / Zhao, Wanhong / Jing, Hongmei / Jin, Jie / Chen, Sai-Juan

European journal of cancer (Oxford, England : 1990)

2023 Volume 188, Page(s) 108–110

MeSH term(s)	Humans ; Receptors, Chimeric Antigen ; Multiple Myeloma/drug therapy ; Immunotherapy, Adoptive/adverse effects ; Receptors, Antigen, T-Cell ; Cell- and Tissue-Based Therapy
Chemical Substances	Receptors, Chimeric Antigen ; Receptors, Antigen, T-Cell
Language	English
Publishing date	2023-05-23
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't ; Comment
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2023.04.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: A Spatio-temporal Bayesian model to estimate risk and influencing factors related to tuberculosis in Chongqing, China, 2014-2020.

Chen, Zhi-Yi / Deng, Xin-Yi / Zou, Yang / He, Ying / Chen, Sai-Juan / Wang, Qiu-Ting / Xing, Dian-Guo / Zhang, Yan

Archives of public health = Archives belges de sante publique

2023 Volume 81, Issue 1, Page(s) 42

Abstract: Background: Tuberculosis (TB) is a serious infectious disease that is one of the leading causes of death worldwide. This study aimed to investigate the spatial and temporal distribution patterns and potential influencing factors of TB incidence risk, ... ...

Abstract	Background: Tuberculosis (TB) is a serious infectious disease that is one of the leading causes of death worldwide. This study aimed to investigate the spatial and temporal distribution patterns and potential influencing factors of TB incidence risk, and to provide a scientific basis for the prevention and control of TB. Methods: We collected reported cases of TB in 38 districts and counties in Chongqing from 2014 to 2020 and data on environment, population characteristics and economic factors during the same period. By constructing a Bayesian spatio-temporal model, we explored the spatio-temporal distribution pattern of TB incidence risk and potential influencing factors, identified key areas and key populations affected by TB, compared the spatio-temporal distribution characteristics of TB in populations with different characteristics, and explored the differences in the influence of various social and environmental factors. Results: The high-risk areas for TB incidence in Chongqing from 2014 to 2020 were mainly concentrated in southeastern and northeastern regions of Chongqing, and the overall relative risk (RR) of TB showed a decreasing trend during the study period, while RR of TB in main urban area and southeast of Chongqing showed an increasing trend. The RR of TB was relatively high in the main urban area for the female population and the population aged 0-29 years, and the RR of TB for the population aged 30-44 years in the main urban area and the population aged 60 years or older in southeast of Chongqing had an increasing trend, respectively. For each 1 μg/m Conclusion: This study showed that high-risk areas for TB were concentrated in the southeastern and northeastern regions of Chongqing, and that the elderly population was a key population for TB incidence. There were spatial and temporal differences in the incidence of TB in populations with different characteristics, and various socio-environmental factors had different effects on different populations. Local governments should focus on areas and populations at high risk of TB and develop targeted prevention interventions based on the characteristics of different populations.
Language	English
Publishing date	2023-03-21
Publishing country	England
Document type	Journal Article
ZDB-ID	1117688-x
ISSN	2049-3258 ; 0778-7367 ; 0003-9578
ISSN (online)	2049-3258
ISSN	0778-7367 ; 0003-9578
DOI	10.1186/s13690-023-01044-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 147: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Poisoning the Devil.

Chen, Zhu / Chen, Sai-Juan

Cell

2017 Volume 168, Issue 4, Page(s) 556–560

MeSH term(s)	Arsenicals/therapeutic use ; China ; France ; History, 20th Century ; History, 21st Century ; Humans ; Leukemia, Promyelocytic, Acute/drug therapy ; Oxides/therapeutic use ; Tretinoin/therapeutic use
Chemical Substances	Arsenicals ; Oxides ; Tretinoin (5688UTC01R) ; arsenic trioxide (S7V92P67HO)
Language	English
Publishing date	2017--09
Publishing country	United States
Document type	Autobiography ; Historical Article ; Journal Article ; Portraits
ZDB-ID	187009-9
ISSN	1097-4172 ; 0092-8674
ISSN (online)	1097-4172
ISSN	0092-8674
DOI	10.1016/j.cell.2017.01.029
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1167: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 58: Show issues

Order via subito

Details ▾

Article ; Online: Mutation associations in RA-defiant APL.

Chen, Sai-Juan

Blood

2012 Volume 120, Issue 10, Page(s) 1969–1970

MeSH term(s)	Antineoplastic Agents/administration & dosage ; Chromosome Aberrations ; Humans ; Leukemia, Promyelocytic, Acute/genetics ; Oncogene Proteins, Fusion/genetics ; Tretinoin/administration & dosage ; fms-Like Tyrosine Kinase 3/genetics
Chemical Substances	Antineoplastic Agents ; Oncogene Proteins, Fusion ; promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein ; Tretinoin (5688UTC01R) ; FLT3 protein, human (EC 2.7.10.1) ; fms-Like Tyrosine Kinase 3 (EC 2.7.10.1)
Language	English
Publishing date	2012-09-06
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2012-07-441303
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Treating leukemia: differentiation therapy for mIDH2 AML.

Sun, Xiao-Jian / Chen, Sai-Juan / Chen, Zhu

Cell research

2019 Volume 29, Issue 6, Page(s) 427–428

MeSH term(s)	Humans ; Leukemia, Myeloid, Acute
Language	English
Publishing date	2019-05-13
Publishing country	England
Document type	Journal Article ; Comment
ZDB-ID	1319303-x
ISSN	1748-7838 ; 1001-0602
ISSN (online)	1748-7838
ISSN	1001-0602
DOI	10.1038/s41422-019-0173-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5283: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.

Yang, Shuangshuang / Xu, Jie / Dai, Yuting / Jin, Shiwei / Sun, Yan / Li, Jianfeng / Liu, Chenglin / Ma, Xiaolin / Chen, Zhu / Chen, Lijuan / Hou, Jian / Mi, Jian-Qing / Chen, Sai-Juan

Nature communications

2024 Volume 15, Issue 1, Page(s) 360

Abstract: Cytokine release syndrome (CRS) is the most common complication of chimeric antigen receptor redirected T cells (CAR-T) therapy. CAR-T toxicity management has been greatly improved, but CRS remains a prime safety concern. Here we follow serum cytokine ... ...

Abstract	Cytokine release syndrome (CRS) is the most common complication of chimeric antigen receptor redirected T cells (CAR-T) therapy. CAR-T toxicity management has been greatly improved, but CRS remains a prime safety concern. Here we follow serum cytokine levels and circulating immune cell transcriptomes longitudinally in 26 relapsed/refractory multiple myeloma patients receiving the CAR-T product, ciltacabtagene autoleucel, to understand the immunological kinetics of CRS. We find that although T lymphocytes and monocytes/macrophages are the major overall cytokine source in manifest CRS, neutrophil activation peaks earlier, before the onset of severe symptoms. Intracellularly, signaling activation dominated by JAK/STAT pathway occurred prior to cytokine cascade and displayed regular kinetic changes. CRS severity is accurately described and potentially predicted by temporal cytokine secretion signatures. Notably, CAR-T re-expansion is found in three patients, including a fatal case characterized by somatic TET2-mutation, clonal expanded cytotoxic CAR-T, broadened cytokine profiles and irreversible hepatic toxicity. Together, our findings show that a latent phase with distinct immunological changes precedes manifest CRS, providing an optimal window and potential targets for CRS therapeutic intervention and that CAR-T re-expansion warrants close clinical attention and laboratory investigation to mitigate the lethal risk.
MeSH term(s)	Humans ; Cytokine Release Syndrome ; Multiple Myeloma/genetics ; Multiple Myeloma/therapy ; Neutrophil Activation ; Receptors, Chimeric Antigen/genetics ; Janus Kinases ; STAT Transcription Factors ; Signal Transduction ; Cytokines
Chemical Substances	Receptors, Chimeric Antigen ; Janus Kinases (EC 2.7.10.2) ; STAT Transcription Factors ; Cytokines
Language	English
Publishing date	2024-01-08
Publishing country	England
Document type	Journal Article
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-023-44648-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.

Xu, Jie / Wang, Bai-Yan / Yu, Shan-He / Chen, Shi-Jun / Yang, Shuang-Shuang / Liu, Rui / Chen, Li-Juan / Hou, Jian / Chen, Zhu / Zhao, Wan-Hong / He, Ai-Li / Mi, Jian-Qing / Chen, Sai-Juan

Journal of hematology & oncology

2024 Volume 17, Issue 1, Page(s) 23

Abstract: Background: The autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ... ...

Abstract	Background: The autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was the first-in-human trial of LCAR-B38M and yielded deep and durable therapeutic responses. Here, we reported the outcomes in LEGEND-2 after a minimal 5-year follow-up. Methods: Participants received an average dose of 0.5 × 10 Results: Seventy-four participants enrolled and had a median follow-up of 65.4 months. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 21.0% and 49.1%, with progressive flattening of the survival curves over time. Patients with complete response (CR) had longer PFS and OS, with 5-year rates of 28.4% and 65.7%, respectively. Twelve patients (16.2%) remained relapse-free irrespective of baseline high-risk cytogenetic abnormality and all had normal humoral immunity reconstituted. An ongoing CR closely correlated with several prognostic baseline indices including favorable performance status, immunoglobulin G subtype, and absence of extramedullary disease, as well as a combination cyclophosphamide and fludarabine preconditioning strategy. Sixty-two (83.8%) suffered progressive disease (PD) and/or death; however, 61.1% of PD patients could well respond to subsequent therapies, among which, the proteasome inhibitor-based regimens benefited the most. Concerning the safety, hematologic and hepatic function recovery were not significantly different between non-PD and PD/Death groups. A low rate of second primary malignancy (5.4%) and no severe virus infection were observed. The patients who tested positive for COVID-19 merely presented self-limiting symptoms. In addition, a sustainable CAR T population of one case with persistent remission was delineated, which was enriched with indolently proliferative and lowly cytotoxic CD4/CD8 double-negative functional T lymphocytes. Conclusions: These data, representing the longest follow-up of BCMA-redirected CAR T-cell therapy to date, demonstrate long-term remission and survival with LCAR-B38M for advanced myeloma. Trial registration: LEGEND-2 was registered under the trial numbers NCT03090659, ChiCTRONH-17012285.
MeSH term(s)	Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; B-Cell Maturation Antigen/immunology ; Follow-Up Studies ; Immunotherapy, Adoptive/methods ; Immunotherapy, Adoptive/adverse effects ; Multiple Myeloma/therapy ; Multiple Myeloma/mortality ; Receptors, Chimeric Antigen/therapeutic use ; Receptors, Chimeric Antigen/immunology ; Remission Induction ; Survival Rate
Chemical Substances	B-Cell Maturation Antigen ; Receptors, Chimeric Antigen ; TNFRSF17 protein, human
Language	English
Publishing date	2024-04-24
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2429631-4
ISSN	1756-8722 ; 1756-8722
ISSN (online)	1756-8722
ISSN	1756-8722
DOI	10.1186/s13045-024-01530-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: National Research Center for Translational Medicine · Shanghai-National Key Scientific Infrastructure for Translational Medicine.

Wen, Chao-Jun / Chen, Sai-Juan

Science China. Life sciences

2016 Volume 59, Issue 10, Page(s) 1051–1054

MeSH term(s)	China ; Hospitals/standards ; Hospitals/trends ; Humans ; Models, Organizational ; Organizational Innovation ; Organizational Objectives ; Patient Care/standards ; Patient Care/trends ; Public Health/standards ; Public Health/trends ; Research Personnel/standards ; Research Personnel/trends ; Translational Medical Research/organization & administration ; Translational Medical Research/standards ; Translational Medical Research/trends ; Universities/standards ; Universities/trends
Language	English
Publishing date	2016-10
Publishing country	China
Document type	News
ISSN	1869-1889
ISSN (online)	1869-1889
DOI	10.1007/s11427-016-5099-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Author Correction: Engineering-enhanced CAR T cells for improved cancer therapy.

Milone, Michael C / Xu, Jie / Chen, Sai-Juan / Collins, McKensie A / Zhou, Jianfeng / Powell, Daniel J / Melenhorst, J Joseph

Nature cancer

2022 Volume 2, Issue 10, Page(s) 1113

Language	English
Publishing date	2022-01-28
Publishing country	England
Document type	Journal Article ; Published Erratum
ISSN	2662-1347
ISSN (online)	2662-1347
DOI	10.1038/s43018-021-00277-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.

Shi, Qing / He, Yang / Yi, Hong-Mei / Mu, Rong-Ji / Jiang, Xu-Feng / Fu, Di / Dong, Lei / Qin, Wei / Xu, Peng-Peng / Cheng, Shu / Song, Qi / Chen, Sai-Juan / Wang, Li / Zhao, Wei-Li

Cancer communications (London, England)

2023 Volume 43, Issue 8, Page(s) 896–908

Abstract: Background: The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) ... ...

Abstract	Background: The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) but whether the same efficacy can be achieved with reduced chemotherapy regimen of four cycles for non-bulky DLBCL patients with an IPI of 1 remains unclear. This study compared four cycles versus six cycles of chemotherapy in non-bulky low-risk DLBCL patients with negative interim positron emission tomography with computed tomography (PET-CT, Deauville 1-3), irrespective of age and other IPI risk factors (IPI 0-1). Methods: This was an open-label, randomized, phase III, non-inferiority trial. Patients aged 14-75 years with newly diagnosed low-risk DLBCL, according to IPI, achieving PET-CT confirmed complete response (CR) after four cycles of R-CHOP were randomized (1:1) between four cycles of rituximab (4R-CHOP+4R arm) or two cycles of R-CHOP plus two cycles of rituximab (6R-CHOP+2R arm). The primary endpoint was 2-year progression-free survival (PFS), conducted in the intention-to-treat population. Safety was assessed in patients with at least one cycle of assigned treatment. The non-inferiority margin was -8%. Results: A total of 287 patients were included in the intention-to-treat analysis, the median follow-up was 47.3 months, and the 2-year PFS rate was 95% (95% confidence interval [CI], 92% to 99%) and 94% (95% CI, 91% to 98%) for the 4R-CHOP+4R and 6R-CHOP+2R arm. The absolute difference in 2-year PFS between the two arms was 1% (95% CI, -5% to 7%), supporting the non-inferiority of 4R-CHOP+4R. Grade 3-4 neutropenia was lower in the last four cycles of rituximab alone in the 4R-CHOP+4R arm (16.7% versus 76.9%), with decreased risk of febrile neutropenia (0.0% versus 8.4%) and infection (2.1% versus 14.0%). Conclusions: For newly diagnosed low-risk DLBCL patients, interim PET-CT after four cycles of R-CHOP was effective in identifying patients with Deauville 1-3 who would have a good response and Deauville 4-5 patients who might have high-risk biological features or develop resistance. Reducing the standard six cycles to four cycles of chemotherapy had comparable clinical efficacy and fewer adverse events in low-risk, non-bulky DLBCL with interim PET-CT confirmed CR.
MeSH term(s)	Humans ; Rituximab ; Positron Emission Tomography Computed Tomography ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Disease-Free Survival ; Lymphoma, Large B-Cell, Diffuse/diagnostic imaging ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Vincristine/adverse effects ; Cyclophosphamide/adverse effects ; Doxorubicin/adverse effects ; Prednisone/adverse effects ; Positron-Emission Tomography/methods ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemical Substances	Rituximab (4F4X42SYQ6) ; Antibodies, Monoclonal, Murine-Derived ; Vincristine (5J49Q6B70F) ; Cyclophosphamide (8N3DW7272P) ; Doxorubicin (80168379AG) ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2023-07-04
Publishing country	United States
Document type	Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2523-3548
ISSN (online)	2523-3548
DOI	10.1002/cac2.12462
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED